Regional lithium prescription rates and recurrence in bipolar disorder.
Bipolar disorder
Drug therapy
Health care quality assessment
Lithium
Outcome assessment
Journal
International journal of bipolar disorders
ISSN: 2194-7511
Titre abrégé: Int J Bipolar Disord
Pays: Germany
ID NLM: 101622983
Informations de publication
Date de publication:
01 Jun 2021
01 Jun 2021
Historique:
received:
14
01
2021
accepted:
02
03
2021
entrez:
1
6
2021
pubmed:
2
6
2021
medline:
2
6
2021
Statut:
epublish
Résumé
Lithium is the best documented maintenance treatment in bipolar disorder, but its use varies considerably across and within countries. It is not known whether regional differences in lithium prescription rates translate to differing regional outcomes. To estimate associations between county specific lithium prescription rates and county specific recurrence odds of bipolar disorder in Sweden. Data from 14,616 patients with bipolar I disorder, bipolar II disorder, or bipolar disorder not otherwise specified were extracted from the Swedish national quality assurance register for bipolar disorders (BipoläR). Lithium prescription frequencies were calculated for 21 counties. Logistic regression analyses were run adjusted for confounders, with any type of recurrence as primary outcome, and incident elated and depressive episodes as secondary outcomes. Subsets of patients with bipolar I, II and not otherwise specified disorder were also analysed separately. Lithium prescription rates for populations with all bipolar subtypes ranged across counties from 37.7 to 84.9% (mean 52.4%). Higher regional prescription rates were significantly associated with lower rate of any type of recurrence. The association was stronger when bipolar I disorder was analysed separately. The advantages for lithium use long acknowledged for bipolar I disorder are also seen for the rest of the bipolar spectrum. Results suggest that population level outcomes of bipolar disorder could be improved by increasing the number of patients using lithium.
Sections du résumé
BACKGROUND
BACKGROUND
Lithium is the best documented maintenance treatment in bipolar disorder, but its use varies considerably across and within countries. It is not known whether regional differences in lithium prescription rates translate to differing regional outcomes.
AIMS
OBJECTIVE
To estimate associations between county specific lithium prescription rates and county specific recurrence odds of bipolar disorder in Sweden.
METHOD
METHODS
Data from 14,616 patients with bipolar I disorder, bipolar II disorder, or bipolar disorder not otherwise specified were extracted from the Swedish national quality assurance register for bipolar disorders (BipoläR). Lithium prescription frequencies were calculated for 21 counties. Logistic regression analyses were run adjusted for confounders, with any type of recurrence as primary outcome, and incident elated and depressive episodes as secondary outcomes. Subsets of patients with bipolar I, II and not otherwise specified disorder were also analysed separately.
RESULTS
RESULTS
Lithium prescription rates for populations with all bipolar subtypes ranged across counties from 37.7 to 84.9% (mean 52.4%). Higher regional prescription rates were significantly associated with lower rate of any type of recurrence. The association was stronger when bipolar I disorder was analysed separately.
CONCLUSIONS
CONCLUSIONS
The advantages for lithium use long acknowledged for bipolar I disorder are also seen for the rest of the bipolar spectrum. Results suggest that population level outcomes of bipolar disorder could be improved by increasing the number of patients using lithium.
Identifiants
pubmed: 34061259
doi: 10.1186/s40345-021-00223-7
pii: 10.1186/s40345-021-00223-7
pmc: PMC8167923
doi:
Types de publication
Journal Article
Langues
eng
Pagination
18Subventions
Organisme : Wenner-Gren Stiftelserna
ID : SSv2019-0008
Organisme : Vetenskapsrådet
ID : 2018-02653
Organisme : Stiftelsen för Strategisk Forskning
ID : KF10-0039
Organisme : Swedish Federal Government under the LUA/ALF agreement
ID : ALFGBG-716801
Références
Bipolar Disord. 2018 Jun;20(4):391-392
pubmed: 29327794
BMJ. 2013 Jun 27;346:f3646
pubmed: 23814104
Lancet Psychiatry. 2014 Oct;1(5):351-9
pubmed: 26360999
Compr Psychiatry. 1964 Dec;5(6):396-408
pubmed: 14238742
J Psychopharmacol. 2016 Jun;30(6):495-553
pubmed: 26979387
Bipolar Disord. 2013 Mar;15(2):115-37
pubmed: 23437958
Arch Gen Psychiatry. 2011 Mar;68(3):241-51
pubmed: 21383262
J Affect Disord. 2007 Apr;99(1-3):9-17
pubmed: 16989907
Soc Psychiatry Psychiatr Epidemiol. 2013 Oct;48(10):1601-10
pubmed: 23754681
J Psychopharmacol. 2012 May;26(5):644-52
pubmed: 21948935
Bull World Health Organ. 2000;78(4):518-20
pubmed: 10885180
Br J Psychiatry. 2017 Mar;210(3):197-202
pubmed: 28104736
Int J Bipolar Disord. 2014 Dec 20;2:15
pubmed: 25530932
Bipolar Disord. 2018 Mar;20(2):97-170
pubmed: 29536616
Educ Health (Abingdon). 2003 Jul;16(2):230
pubmed: 14741909
JAMA Psychiatry. 2013 Sep;70(9):931-9
pubmed: 23863861
BMJ. 2014 Sep 25;349:g5673
pubmed: 25258392
Lancet. 2013 May 11;381(9878):1672-82
pubmed: 23663953
PLoS One. 2011;6(12):e28725
pubmed: 22163329
Int J Neuropsychopharmacol. 2017 Feb 1;20(2):180-195
pubmed: 27941079
Arch Gen Psychiatry. 2005 Dec;62(12):1322-30
pubmed: 16330720
World J Biol Psychiatry. 2013 Apr;14(3):154-219
pubmed: 23480132
J Intern Med. 2015 Jan;277(1):94-136
pubmed: 25174800
Am J Psychiatry. 2002 Jun;159(6):1005-10
pubmed: 12042190
Am J Psychiatry. 2020 Aug 1;177(8):706-715
pubmed: 32312111
Am J Psychiatry. 2017 Aug 1;174(8):795-802
pubmed: 28595491
J Affect Disord. 2016 May;195:50-6
pubmed: 26859073
Br J Psychiatry. 1963 Nov;109:810-4
pubmed: 14080575
J Affect Disord. 2006 Apr;91(2-3):273-6
pubmed: 16483670
Bipolar Disord. 2016 Mar;18(2):174-82
pubmed: 26890465
Braz J Psychiatry. 2020 Sep 18;:
pubmed: 32965432
Br J Psychiatry. 2011 Jul;199(1):57-63
pubmed: 21593515